Synthesis and Antitumor Activity of Sulfur-Containing 9-Anilinoacridines

Kun-Ming Chen, Yuan-Wan Sun, Yu-Wei Tang, Zhong-Yue Sun, and Chul-Hoon Kwon*

Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John’s University, Jamaica, New York 11439

Received September 9, 2004

Abstract: A series of sulfur-containing 9-anilinoacridines related to amsacrine were synthesized and evaluated for their anticancer potential. Among the compounds, both diol-containing compounds, 2a and 3, were the most cytotoxic of the sulfide series against V-79 cells in vitro (IC₉₀ = 2.1 μM and 1.9 μM, respectively). Among the non-alkyl-substituted compounds (7–9), compounds with electron-donating substitution para to the sulfide (7 and 9) were more cytotoxic than the electron-withdrawing nitro-substituted compound 8. The limited SAR suggested the importance of hydroxyl functionality along with its location for the cytotoxicity in the series. A preliminary anticancer screening against P388 leukemia showed that 2a is highly active in vivo as well. Topoisomerase II inhibitory activity appeared to be involved in the cytotoxicity of compound 2a. Sulfoxide compound 2b, which is 6–7-fold less cytotoxic than its sulfide 2a, appears to be a potential bioreductive anticancer prodrug on the basis of its bioreductive metabolism findings.

Keywords: Amsacrine; 9-anilinoacridines; V-79 Chinese hamster lung fibroblasts; bioreductive anticancer prodrug; topoisomerase II

Introduction

The primary medicinal interest in intercalating agents has been their potential as anticancer drugs; in 1978, the acridine derivative amsacrine (m-AMSA; Chart 1), a 9-anilinoacridine, became the first synthetic DNA-intercalating agent to be clinically successful. The drug is thought to be held on location through intercalation until a crucial event, such as a change in supercoiling catalyzed by a DNA topoisomerase, occurs. DNA topoisomerase II has been identified as the intracellular target for amsacrine and several other anticancer drugs.

Chart 1

It has been reported that the presence of a substituent at position 1′ of the anilinoacridine chromophore is required to permit the drug to interfere with the catalytic activity of topoisomerase II. By varying the nature of this side chain...

* Author to whom correspondence should be addressed. Mailing address: Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John’s University, 8000 Utopia Parkway, Jamaica, NY 11439. Tel: (718)-990-5214. Fax: (718)-990-6551. E-mail: kwonc@stjohns.edu.


10.1021/mp049913g CCC: $30.25 © 2005 American Chemical Society
Published on Web 02/04/2005
at position 1′, one can expect to change the capacity of the drug to interfere with topoisomerase II so as to modulate its cytotoxicity. It has been found that certain anilinoacridine derivatives having a sterically demanding substituent at position 1′ remained cytotoxic. For example, SN 12489 (NSC 140701, Chart 1) was found to be as efficient as amsacrine at prompting DNA cleavage by topoisomerase II, and the level of DNA lesions produced by the drug in cells correlated well with its cytotoxicity.

It had been previously found in our laboratory that certain sulfoxides were selectively bioreduced under anaerobic conditions in vitro. Subsequently, several types of sulfoxide-containing molecules were designed and explored as potential bioreductive cytotoxins. Among the compounds, 4-[N,N-bis(chloroethyl)]amino-4′-(9-acridinyl)aminodiphenyl sulfoxide, an acridine-substituted diphenyl sulfoxide nitrogen mustard (1b, Chart 2), showed an excellent hypoxia selectivity (27-fold), and the putative active drug, the corresponding sulfide (1a, Chart 2), was 14 times as cytotoxic as the sulfoxide against V-79 cells. It was, however, unclear whether the acridine moiety provided any contribution to the overall cytotoxicity profile through a possible DNA intercalation, especially in view of the structural similarity of 1a to amsacrine analogues, for example, SN 12489. Studies on structurally related acridine-containing alkylphenyl sulfoxide mustard (23) demonstrated that topoisomerase II inhibition is responsible for its cytotoxicity but not DNA alkylation.

In this report, a series of nonalkylating analogues of 1a (Chart 3) were synthesized and their anticancer potential was evaluated through in vitro cytotoxicity. In addition, the possible mechanism of cytotoxicity was evaluated. The corresponding sulfoxides of selected compounds were also synthesized as potential bioreductive prodrugs along with their corresponding sulfones. An in vitro metabolism study of sulfoxide 2b was also performed to evaluate the bioreductive potential.

**Experimental Section**

**Chemistry.** Melting points were determined on a Thomas-Hoover capillary melting point apparatus and were uncorrected. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Mass spectroscopy was performed by Mass Consortium, San Diego, CA. The following instruments were used: IR, Perkin-Elmer model 281; 1H NMR, Varian EM-360L CW, 400 MHz (TMS as internal standard). Silica gel GF plates (Analtech) were used for TLC (250 μm, 2.5 × 10 cm) and preparative TLC (1000 μm, 20 × 20 cm). Silica gel (40 μm, Baker) was used for flash column chromatography. All chemicals and solvents were reagent grade and were purchased from commercial vendors.

2-((2-Hydroxyethyl)[4-(4-nitrophenylthio)phenyl]amino)ethan-1-ol (10a) was prepared according to a previously published procedure. 2-((2-Hydroxyethyl)[4-(4-nitrophenylsulfinyl)phenyl]amino)ethan-1-ol (10b). To a solution of 10a (1.5 g, 4.49 mmol) in trifluoroacetic acid (TFA, 7.11 mL) was added 1.98 mL of CF3 CO3 H (4.49 mmol, prepared by mixing 0.46 mL of 30% H2O2 with 1.52 mL of TFA) with stirring and ice-cooling. The blue reaction mixture turned green after 185 min; the mixture was neutralized with NaHCO3. The resulting mixture was extracted with EtOAc (3 × 50 mL). EtOAc extracts were combined, washed with H2O (30 mL), and then dried over Na2SO4. Orange crystalline 10b (0.99 g, 63% yield) was obtained after crystallization from EtOAc/hexane: mp 134–136 °C; TLC Rf = 0.43 in CH3Cl/CH3OH (9:1); 1H NMR (CDCl3) δ 3.50–3.80 (m, 2H); 4.8 (br s, 2H); 6.75 (d, J = 8.8 Hz, 2H); 7.44 (d, J = 8.8 Hz, 2H); 7.80 (d, J = 8.9 Hz, 2H); 8.27 (d, J = 8.8 Hz, 2H). Anal. (C16H18N2O5S) C, H, N, S.

2-((2-Hydroxyethyl)[4-(4-nitrophenylsulfonyl)phenyl]amino)ethan-1-ol (10c). To a solution of 10a (1.5 g, 4.49 mmol) in trifluoroacetic acid (TFA, 5 mL) was added 2.73 mL of CF₃CO₂H (8.98 mmol, prepared by mixing 0.93 mL of 30% H₂O₂ with 1.8 mL of TFA) with stirring and ice-cooling. The blue reaction mixture turned green after 8 h; then was neutralized by adding 50% NaHCO₃ (14.8 mL) solution. The resulting mixture was extracted with EtOAc (3 × 100 mL). The combined EtOAc extracts were washed with H₂O (30 mL) once and then dried over anhydrous Na₂SO₄. After EtOAc was evaporated in vacuo, compound 10b (0.44 g, 27% yield) was purified by flash column chromatography with EtOAc as the eluting solvent: mp 193–195 °C; TLC R₇ = 0.41 in EtOAc; ¹H NMR (CDCl₃) δ 3.33–3.73 (m, 8H), 4.73 (br s, 2H), 6.83 (d, J = 9.0 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.93–8.50 (m, 4H).

2-((4-Aminophenylthio)phenyl)(2-hydroxyethyl)amino)ethan-1-ol (11a). Iron powder (19.12 g, 100 mesh) was activated by refluxing it with 4 mL of distilled water (30 mL) and extracted with EtOAc (3 × 100 mL) was then added to the mixture at 40 °C. After evaporation of EtOH, the residue was diluted with water (30 mL) and extracted with EtOAc (3 × 100 mL). The EtOAc extract was dried over anhydrous Na₂SO₄ and evaporated in vacuo. The crude product was then mixed with 10 mL of CF₃CO₂H (8.98 mmol, prepared by mixing 0.93 mL of 30% H₂O₂ with 1.8 mL of TFA) with stirring and ice-cooling. Ethanol (33 mL) and 21 drops of concentrated hydrochloric acid for 30 min was added into the mixture at 40 °C; TLC R₇ = 0.46 in EtOAc/EtOH (9:1); ¹H NMR (CDCl₃/CD₃OD, 1:1) δ 3.50–3.83 (m, 8H), 6.58–6.77 (m, 4H), 7.20–7.40 (m, 4H). Anal. (C₁₆H₂₀N₂O₂S) C, H, N, S.

2-((4-Aminophenylsulfanyl)phenyl)(2-hydroxyethyl)amino)ethan-1-ol (11b) was prepared from 10b on a 2.86-mmol scale (1.00-g) according to the procedure for 11a to give 0.57 g (62% yield) of 11b after flash column purification using EtOAc/EtOH (9:1) as eluent: mp 118.5–121 °C; TLC R₇ = 0.41 in EtOAc; ¹H NMR (CDCl₃) δ 3.37–3.67 (m, 8H), 6.45–6.67 (m, 4H), 6.97–7.20 (m, 4H). Anal. (C₁₆H₂₀N₂O₂S) C, H, N, S.

2-((4-Acridin-9-ylamino)phenylthio)phenyl)(2-hydroxyethyl)amino)ethan-1-ol hydrochloride (2a) was prepared by dissolving 11a (0.31 g, 1.03 mmol) and 9-chloroacridine (0.22 g, 1.03 mmol) in N-methyl-2-pyrolidinone (10 mL) with the addition of 1 drop of concentrated HCl. The reaction mixture was stirred for 4 h at room temperature; EtOAc (100 mL) was then added to precipitate out the crude product. The crude product was then mixed with 10 mL of N-methyl-2-pyrolidinone again for 1 h, followed by addition of EtOAc (150 mL) for complete precipitation. The resulting precipitate was collected to give 0.37 g (69% yield) of compound 2a as a red solid: mp 163–165 °C dec; TLC R₇ = 0.76 in EtOAc/MeOH (9:5:0.5); ¹H NMR (CDCl₃/DMSO-d₆, 2:1) δ 3.60 (s, 8H), 6.77 (d, J = 8.6 Hz, 2H), 7.17–7.57 (m, 8H), 7.90–8.4 (m, 6H). Anal. (C₂₃H₂₁N₂O₂S·HCl) C, H, N, S.

2-((4-Acridin-9-ylamino)phenylsulfonyl)phenyl)(2-hydroxyethyl)amino)ethan-1-ol hydrochloride (2b) was prepared from 11b (0.48 g, 1.5 mmol) and 9-chloroacridine (0.3 g, 1.4 mmol) according to the procedure for 2a to give 0.72 g (90% yield) of 2b as a yellow solid: mp 193–195 °C dec; TLC R₇ = 0.37 in EtOAc/EtOH (9:1); ¹H NMR (CDCl₃/DMSO-d₆, 2:1) δ 3.52 (s, 8H), 6.79 (d, J = 8.6 Hz, 2H), 7.32–8.31 (m, 14H). Anal. (C₂₅H₂₃N₂O₃S·HCl) C, H, N, S.

2-((4-Acridin-9-ylamino)phenylsulfonyl)phenyl)(2-hydroxyethyl)amino)ethan-1-ol hydrochloride (2c) was prepared from 11c (0.18 g, 0.55 mmol) and 9-chloroacridine (0.11 g, 0.51 mmol) according to the procedure for 2a to give 0.22 g (73% yield) of 2c: mp 248–249.5 °C dec; TLC R₇ = 0.75 in EtOAc/EtOH (9:1); ¹H NMR (CDCl₃/DMSO-d₆, 2:1) δ 3.52 (s, 8H), 6.78 (d, J = 9.0 Hz, 2H), 7.37–8.40 (m, 14H). Anal. (C₂₅H₂₃N₂O₃S·HCl) C, H, N, S.

4-([4-(Acridin-9-ylamino)phenyl]sulfonyl)phenyl(morphine (13a) was prepared according to a published procedure with some modifications. A cooled (0 °C) solution containing 10a (2.55 g, 7.63 mmol) in 20 mL of anhydrous THF was treated with diethyl azodicarboxylate (2 g, 11.3 mmol) and tributylphosphine (2.35 g, 11.3 mmol) under N₂. The reaction mixture was then mixed with 10 mL of CH₂Cl₂ (3 × 100 mL). The CH₂Cl₂ extract was then mixed with 10 mL of anhydrous Na₂SO₄ and evaporated in vacuo. The crude product was then mixed with 10 mL of CH₂Cl₂ (3 × 100 mL). The CH₂Cl₂ extract was then mixed with 10 mL of anhydrous Na₂SO₄ and evaporated in vacuo. The crude product was then mixed with 10 mL of CH₂Cl₂ (3 × 100 mL). The CH₂Cl₂ extract was then mixed with 10 mL of anhydrous Na₂SO₄ and evaporated in vacuo.
according to the procedure for 10b to give 1.08 g (70% yield) of 13b after further crystallization with EtOAc/hexane: mp 159.5–161 °C; TLC \( R_f = 0.23 \) in EtOAc/CH\(_2\)Cl\(_2\) (1:9); \(^1\)H NMR (CDCl\(_3\)/CD\(_2\)OD, 1:1) \( \delta \) 3.22 (t, \( J = 4.8 \) Hz, 4H), 3.82 (t, \( J = 4.8 \) Hz, 4H), 6.88 (d, \( J = 8.8 \) Hz, 2H), 7.43–7.87 (m, 4H), 8.28–8.36 (d, \( J = 8.8 \) Hz, 2H).

4-[(4-Nitrophenyl)sulfonyl]phenyl)morpholine (13c). To a solution of 13a (1.22 g, 3.86 mmol) in 125 mL acetone and 20 mL of water was added a mixture of 38 mL of 30% (wt) of hydrogen peroxide (252 mmol) and 6 mL of 0.3 M ammonium molybdate. The reaction mixture was stirred at room temperature overnight; then the mixture was evaporated in vacuo. The residue was partitioned between EtOAc (40 mL) and water (20 mL). The water layer was extracted with EtOAc (3 × 100 mL). The organic extract was washed with water (20 mL) and was crystallized with EtOAc/hexane to give 0.64 g (48% yield) of 13c as yellow crystals: mp 201–202.5 °C; TLC \( R_f = 0.44 \) in EtOAc/hexane (1:1); \(^1\)H NMR (CDCl\(_3\)) \( \delta \) 3.36 (t, \( J = 5.0 \) Hz, 4H), 3.81 (t, \( J = 4.8 \) Hz, 4H), 6.85 (d, \( J = 9.0 \) Hz, 2H), 7.23–8.33 (m, 6H).

4-[(4-Morpholin-4-ylphenyl)thio]aniline (14a) was prepared from 13a on a 1.96-mmol (0.62-g) scale in the procedure for 11a to give 0.25 g (45% yield) of 14a after flash column purification using EtOAc as eluent: mp 141–143 °C; TLC \( R_f = 0.42 \) in EtOAc/CH\(_2\)Cl\(_2\) (1:9); \(^1\)H NMR (CDCl\(_3\)) \( \delta \) 3.09 (t, \( J = 5.0 \) Hz, 4H), 3.83 (t, \( J = 4.8 \) Hz, 4H), 6.50–7.25 (m, 8H).

4-[(4-Morpholin-4-ylphenyl)sulfinyl]aniline (14b) was prepared from 13b on a 2.67-mmol (0.89-g) scale in the procedure for 11a to give 0.66 g (82% yield) of 14b after flash column purification using EtOAc as eluent: mp 168–170 °C; TLC \( R_f = 0.55 \) in EtOAc; \(^1\)H NMR (CDCl\(_3\)) \( \delta \) 3.07 (t, \( J = 4.8 \) Hz, 4H), 3.77 (t, \( J = 5.0 \) Hz, 4H), 6.56–7.48 (m, 8H).

4-[(4-Morpholin-4-ylphenyl)sulfonyl]aniline (14c) was prepared from 13c on a 1.78-mmol (0.62-g) scale in the procedure for 11a to give 0.48 g (85% yield) of 13c after flash column purification using EtOAc/CH\(_2\)Cl\(_2\) (1:9) as eluent: mp 176–178 °C; TLC \( R_f = 0.33 \) in EtOAc/CH\(_2\)Cl\(_2\) (1:9); \(^1\)H NMR (CDCl\(_3\)) \( \delta \) 3.22 (t, \( J = 5.0 \) Hz, 4H), 3.77 (t, \( J = 5.0 \) Hz, 4H), 6.54–6.96 (m, 4H), 7.41–7.73 (m, 4H). N-(4-[(4-Morpholin-4-ylphenyl)thio]phenyl)acridin-9-amine hydrochloride (4a) was prepared from 14a (0.20 g, 0.71 mmol) and 9-chloroacridine (0.14 g, 0.64 mmol) according to the procedure for 2a to give 0.32 g (90% yield) of 4a as an orange solid: mp 295 °C dec; TLC \( R_f = 0.49 \) in EtOAc/hexane (1:1); \(^1\)H NMR (CDCl\(_3\)/DMSO-d\(_6\), 2:1) \( \delta \) 3.04 (t, \( J = 5.0 \) Hz, 4H), 3.68 (t, \( J = 5.0 \) Hz, 4H), 6.60–7.90 (m, 16H). Anal. (C\(_{29}\)H\(_{25}\)N\(_3\)O\(_2\)S•HCl•H\(_2\)O) C, H, N, S.

N-(4-[(4-Morpholin-4-ylphenyl)sulfonyl]phenyl)acridin-9-amine hydrochloride (4b) was prepared from 14b (0.35 g, 1.16 mmol) and 9-chloroacridine (0.25 g, 1.17 mmol) according to the same procedure for 2a to give 0.56 g (93% yield) of 4b: mp 232–234 °C dec; TLC \( R_f = 0.58 \) in EtOAc; \(^1\)H NMR (CDCl\(_3\)/DMSO-d\(_6\), 2:1) \( \delta \) 3.23–3.40 (m, 4H), 3.70–3.86 (m, 4H), 7.02 (d, \( J = 8.6 \) Hz, 2H), 7.33–8.30 (m, 14H). Anal. (C\(_{30}\)H\(_{25}\)N\(_3\)O\(_2\)S•HCl•H\(_2\)O) C, H, N, S.

4-[[4-(4-Methylpiperazin-1-yl)phenyl]thio]aniline (16a) was prepared from 15a on a 2.94-mmol (0.97-g) scale in the procedure for 11a to give 0.68 g (78% yield) of 16a after flash column purification using CH₂Cl₂/MeOH/TEA (95:5:1) as eluent: mp 145–146 °C; TLC Rₓ = 0.21 in CH₂Cl₂/MeOH/TEA (95:5:1); ¹H NMR (CDCl₃) δ 2.33 (s, 3H), 2.58 (t, J = 4.9 Hz, 4H), 3.22 (t, J = 4.9 Hz, 4H), 6.51–7.26 (m, 8H).

4-[[4-(4-Methylpiperazin-1-yl)phenyl]sulfonyl]aniline (16b) was prepared from 15b on a 2.06-mmol (0.71-g) scale in the procedure for 11a to give 0.39 g (60% yield) of 16b after flash column purification using CH₂Cl₂/MeOH/TEA (95:5:1) as eluent: mp 179–180.5 °C; TLC Rₓ = 0.37 in CH₂Cl₂/MeOH/TEA (95:5:1); ¹H NMR (CDCl₃) δ 2.31 (s, 3H), 2.52 (t, J = 5.0 Hz, 4H), 3.25 (t, J = 5.0 Hz, 4H), 6.56–7.50 (m, 8H).

4-[[4-(4-Methylpiperazin-1-yl)phenyl]sulfonyl]aniline (16c) was prepared from 15c on a 3.00-mmol (1.08-g) scale in the procedure for 11a to give 0.69 g (69% yield) of 16c after purification with preparative TLC using CH₂Cl₂/MeOH/TEA (95:5:1) as eluent: mp 188–190 °C dec; TLC Rₓ = 0.54 in CH₂Cl₂/MeOH (9:1); ¹H NMR (CDCl₃) δ 2.30 (s, 3H), 2.51 (t, J = 4.8 Hz, 4H), 3.27 (t, J = 4.8 Hz, 4H), 6.69 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H) 7.58 (d, J = 8.5 Hz, 2H) 7.67 (d, J = 8.5 Hz, 2H).

N-[[4-[[4-(4-Methylpiperazin-1-yl)phenyl]thio]phenyl]acridin-9-amine dihydrochloride (5a) was prepared from 16a (0.20 g, 0.67 mmol) and 9-chloroacridine (0.14 g, 0.65 mmol) according to the procedure for 2a to give 0.31 g (83% yield) of 5a as a red solid: mp 211–213 °C; TLC Rₓ = 0.45 in CH₂Cl₂/MeOH (9:1). Compound 5a (0.18 g, 0.32 mmol) was then partitioned between CH₂Cl₂ (250 mL) and saturated Na₂CO₃ solution. The water layer was extracted with CH₂Cl₂ (3 x 100 mL). The combined CH₂Cl₂ was dried over anhydrous Na₂SO₄ and evaporated to give 0.10 g (62% yield) of the free base of 5a for elemental analysis: ¹H NMR for the free base form of 5a (CDCl₃) δ 2.33 (s, 3H), 2.60–2.70 (m, 4H), 3.13–3.27 (m, 4H), 6.68–8.04 (m, 16H). Anal. (C₃₄H₂₆N₄S) C, H, N, S.

N-[[4-[[4-(4-Methylpiperazin-1-yl)phenyl]sulfonyl]phenyl]acridin-9-amine dihydrochloride (5b) was prepared from 16b (0.26 g, 0.84 mmol) and 9-chloroacridine (0.19 g, 0.89 mmol) according to the procedure for 2a to give 0.40 g (85% yield) of 5b as an orange solid: mp 225–227 °C; TLC Rₓ = 0.51 in CH₂Cl₂/MeOH (9:1); ¹H NMR (CDCl₃) δ 2.30 (s, 3H), 2.49 (t, J = 5.0 Hz, 4H), 3.23 (t, J = 5.0 Hz, 4H), 6.74–8.00 (m, 16H). Anal. (C₃₄H₂₆N₄OS·2HCl·½H₂O) C, H, N, S.

N-[[4-[[4-(4-Methylpiperazin-1-yl)phenyl]sulfonyl]phenyl]acridin-9-amine dihydrochloride (5c) was prepared from 16c (0.21 g, 0.62 mmol) and 9-chloroacridine (0.16 g, 0.73 mmol) according to the procedure for 2a to give 0.36 g (99% yield) of 5c as an orange solid: mp 229 °C dec; TLC Rₓ = 0.58 in CH₂Cl₂/MeOH (9:1); ¹H NMR for the free base form of 5c (CDCl₃) δ 2.36 (s, 3H), 2.55 (t, J = 5.2 Hz, 4H), 3.33 (t, J = 5.1 Hz, 4H), 6.78–7.96 (m, 16H). Anal. (C₃₄H₂₆N₄OS·2HCl·H₂O) C, H, N, S.

2-[(4-[[4-Nitrophenyl]thio]phenyl]amino)ethanol (17) was prepared from 4-amino-4′-nitrodiphenyl sulfide (10 g, 40 mmol) and a mixture of THF (50 mL), AcOH (100 mL), and 20 mL of 10% (w/v) of ethylene oxide in THF (45.40 mmol) according to the similar procedure for 10a. The reaction solution was stirred at room temperature overnight. The mixture was then neutralized with saturated Na₂CO₃, and extracted with EtOAc (4 x 150 mL). The EtOAc extract was then dried over anhydrous Na₂SO₄ and evaporated in vacuo, and compound 17 (5.21 g, 44% yield) was purified by flash chromatography using acetone/CH₂Cl₂ (1:9) as eluent: mp 92–94 °C; TLC Rₓ = 0.72 in acetone/CH₂Cl₂ (1:9); ¹H NMR (CDCl₃) δ 3.37 (t, J = 5.0 Hz, 2H), 3.81 (t, J = 5.0 Hz, 2H), 6.64–7.45 (m, 6H), 8.05 (d, J = 9.0 Hz, 2H).

2-[(4-[[4-Aminophenyl]thio]phenyl]amino)ethanol hydrochloride (6) was prepared from 18 (0.36 g, 1.39 mmol) and 9-chloroacridine (0.32 g, 0.16 mmol) according to the procedure for 2a to give 0.24 g (36% yield) of 6: mp 263–265 °C dec; TLC Rₓ = 0.75 in CH₂Cl₂/MeOH (9:1); ¹H NMR (CDCl₃) δ 3.13 (t, J = 5.7 Hz, 2H), 3.57 (t, J = 5.7 Hz, 2H), 6.69 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.1 Hz, 2H), 7.29 (t, J = 8.9 Hz, 4H), 7.44 (t, J = 8.3, 4H), 7.97 (t, J = 7.8 Hz, 2H), 8.08 (d, J = 7.8 Hz, 2H), 8.24 (d, J = 7.8 Hz, 2H). Anal. (C₂₇H₂₃N₂OS·HCl) C, H, N, S.

N-[[4-[(4-Nitrophenyl)thio]phenyl]acridin-9-amine dihydrochloride (8) was prepared from 9-chloroacridine (0.71 g, 3.32 mmol) and 4-amino-4′-nitrodiphenyl sulfide (0.81 g, 3.27 mmol) according to the procedure for 2a to give 1.50 g (100% yield) of 8: mp >290 °C; TLC Rₓ = 0.36 in CH₂Cl₂/MeOH (9:6:0.4); ¹H NMR of 8 (DMSO-d₆) δ 7.37 (d, J = 9.0 Hz, 2H), 7.56 (m, 4H), 7.68 (d, J = 8.0 Hz, 2H), 8.0 (t, J = 8.0 Hz, 2H), 8.19–8.22 (m, 4H), 8.35 (d, J = 8.8 Hz, 2H). Anal. (C₂₇H₂₃N₂S·2HCl·H₂O) C, H, N, S; MS m/z 394 (MH+).

4-[[4-Nitrophenyl]thio]phenol (19). To a solution of 4-amino-4′-nitrodiphenyl sulfide (5 g, 20.3 mmol) and acetone (30 mL) was added 14 mL of hot 35% sulfuric acid while the temperature was kept under 5 °C. A solution of 1.63 g of sodium nitrite in 4.47 mL of ice water was then added dropwise, and 0.15 g of urea in 15.23 g ice water.
was added 5 min later. A boiling solution containing 5.5 mL of sulfuric acid and 5 mL of water was then added into the reaction mixture. The mixture was refluxed for 5 h. The resulting solution was then extracted with EtOAc (3 × 100 mL) and washed with NaHCO₃ and brine successively. The EtOAC extract was dried over anhydrous Na₂SO₄ and evaporated in vacuo. The residue was partitioned 1 g of potassium carbonate. After being refluxed for 15 h, the nitrodiphenyl sulfide (2.5 g, 10 mmol) and 3-iodopropanol (CDCl₃) was given 2.52 g (51% yield) of 19; mp 150–151 °C; TLC Rf = 0.42 in EtOAc/hexane (1:3) as the eluting solvent to give 2.52 g (51% yield) of 19: mp 150–151 °C: TLC Rf = 0.42 in EtOAc/hexane (1:3); ¹H NMR (CDCl₃) δ 6.85 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.91 (d, J = 8.5 Hz, 2H) 9.33 (s, 1H).

4-[(4-Aminophenyl)thiophenol]phenol hydrochloride (9) was prepared from 20 (0.12 g, 0.48 mmol) and 9-chloroacridine (0.11 g, 0.51 mmol) according to the procedure for 2a to give 0.44 g (83% yield) of 9: mp 279–281.5 °C; TLC Rf = 0.40 in CH₂Cl₂/MeOH (9:5:0.5); ¹H NMR (DMSO-d₆) δ 10.04 (s, 1H, OH), 6.90 (d, J = 8.5 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 7.39–7.35 (m, 4H), 7.46 (t, J = 7.5 Hz, 2H), 7.99 (t, J = 7.8 Hz, 2H), 8.12 (d, J = 8.5 Hz, 2H), 8.27 (d, J = 8.5 Hz, 2H). Anal. (C₂₁H₁₈N₂O₄S·HCl) C, H, N.

3-[(3-Hydroxypropyl)-4-[(4-nitrophenyl)thiophenol]-amino]propan-1-ol (21). To a solution of 4-aminoo-4′-nitrodiphenyl sulfide (2.5 g, 10 mmol) and 3-iodopropanol (3.89 g, 20 mmol) in dry THF (10 mL) was added a mixture of tetrabutylammonium bromide (0.16 g, 0.5 mmol) and 5.5 g of potassium carbonate. After being refluxed for 15 h, the mixture was evaporated in vacuo. The residue was partitioned between CH₂Cl₂ (60 mL) and water (30 mL). The water layer was extracted with CH₂Cl₂ (3 × 100 mL). The CH₂Cl₂ extract was dried over anhydrous Na₂SO₄ and evaporated in vacuo. Compound 21 (0.6 g, 17% yield) was purified by flash column chromatography using EtOAc as eluting solvent: TLC Rf = 0.59 in EtOAc/MeOH (10:1); ¹H NMR (CDCl₃) δ 1.88–1.95 (m, 4H), 3.54 (t, J = 7.3 Hz, 4H), 3.78 (t, J = 6.0 Hz, 4H), 6.80 (d, J = 9.0 Hz, 2H), 7.11 (d, J = 9.2 Hz, 2H), 7.38 (d, J = 9.0 Hz, 2H), 8.05 (d, J = 9.0 Hz, 2H).

3-[(4-[(4-Aminophenyl)thiophenol]-3-hydroxypropylamino]propan-1-ol hydrochloride (3) was prepared from 22 (0.28 g, 0.85 mmol) and 9-chloroacridine (0.18 g, 0.85 mmol) by the procedure for 2a to give 0.72 g (90% yield) of 3 as a yellow solid; mp 149–152 °C; TLC Rf = 0.37 in EtOAc/EtOH (9:1); ¹H NMR (CDCl₃/DMSO-d₆, 2:1) δ 1.65–1.70 (m, 4H), 3.40 (t, J = 7.1 Hz, 4H), 3.45 (t, J = 6.0 Hz, 4H), 6.88 (s, br, 2H), 7.18 (d, J = 7.8 Hz, 2H), 7.35 (d, J = 8.2 Hz, 4H), 7.48 (t, J = 7.3 Hz, 2H), 7.99–8.05 (m, 4H), 8.23 (d, J = 8.7 Hz, 2H). Anal. (C₂₃H₂₃N₃O₄S·HCl·H₂O) C, H, N, S; MS mlz 510 (MH⁺), 508 ([M – H]⁻).

**In Vitro Clonogenic Cytotoxicity Assay.** The published procedure of Fracasso and Sartorelli with some modification was used. The Chinese hamster lung transformed V-79 cells were used for in vitro cytotoxicity evaluations. A confluent dish of the V-79 cells was washed with 5 mL of sterile HBSS twice and followed by treatment with 0.25% trypsin (Gibco labs) for 5 min. Care was made to verify that all cells were floating in the solution. After centrifugation, the precipitated cells were resuspended with medium and collected. The cells were counted by trypan blue dye exclusion with a bright-line hemocytometer (Fisher Inc). In each Petri dish, 50000 cells were seeded in 10 mL of minimum essential medium supplemented with 10% heat inactivated fetal bovine serum, penicillin G sodium, streptomycin sulfate, amphotericin, nonessential amino acids, and vitamins (Gibco, Grand Island, NY) and then incubated for 24 h in a 95% air/5% CO₂ humidified atmosphere. The medium was then removed, and cells were fed with 10 mL of fresh medium.

The testing drugs were first dissolved in DMF as stock solution; then the stock solutions were further diluted with DMF to appropriate concentrations before being added into the cultured cells. After 3 h of drug exposure, the cells were washed twice with 5 mL of sterile HBSS and treated with 0.25% trypsin (Gibco Labs) for 5 min. Cells were collected by centrifugation, resuspended in fresh medium, and counted by trypan blue dye exclusion. After an appropriate dilution, 500 cells were plated in triplicate in 10 mL of medium. After 6–8 days of incubation to allow colony formation, colonies were rinsed with 0.9% saline twice, fixed with ethanol, stained with crystal violet, and counted. Results were reported as the number of colonies that survived chemical treatment per number of colonies in the solvent-treated control. The LC₅₀ values were determined by semilogarithmically plotting the drug concentration versus cell viability as determined by the number of colonies that survived the treatments.

**Topoisomerase II Inhibitory Study.** The topoisomerase II inhibitory assay was performed using the topoisomerase II drug screening kit (TopoGen, Inc., Columbus, OH). The pRYG DNA was used as DNA substrate in this assay.

The final reaction volume was 20 µL, which included 2 µL of cleavage buffer (30 mM Tris-HCl, pH 7.6, 3 mM ATP, 508 (M⁻H)⁻.

---

(13) Fracasso, P. M.; Sartorelli, A. C. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res. 1986, 46, 3939–3944.
15 mM mercaptoethanol, 8 mM MgCl₂, and 60 mM NaCl), 1 μL of supercoiled pRYG DNA (0.25 μg/μL), with or without 2 μL of drug solution and varying amounts of enzyme, which was added last. The optimal amount of topoisomerase II (2 units/μL) needed to cause DNA relaxation was predetermined by incubating different amounts of topoisomerase II (1–4 μL) with DNA substrate (1 μL). The incubations carried out with and without 10% DMSO were both used as negative control in each assay, and amsacrine was used to serve as positive control.

The incubations were carried out at 37 °C for 30 min; then 16 μL of each reaction mixture was loaded onto agarose gel after addition of 2 μL of loading buffer (0.25% bromophenol blue, 50% glycine) into the mixture. Samples were electrophoresed on a 1% agarose gel containing 0.5 g/mL EtBr at 90 V for 2 h in TAE buffer (Tris-Acetate-EDTA buffer, Sigma) also containing 0.5 g/mL EtBr. The 10 TAE buffer contains 0.4 M Tris acetate (pH 8.3) and 0.01 M EDTA. After destaining for 30 min in water, agarose gels were photographed (Polaroid, 667 film, 0.5 sec, f/11) under UV illumination by a UV transilluminator (Ultra-Lum, Inc).

In Vitro Bioreduction Study. The rat S-9 fraction was prepared essentially as previously reported. 7 The final incubation volume was 3 mL, which consists of 50 μL (5 μmol) of the tested drug in DMF, 50 μL (5 μmol) of cofactor in DMF, and 2 mL of S-9 fraction. Cofactors used were benzaldehyde (0.1 M, in DMF), 2-hydroxypropyramidine (0.1 M, in DMF), NADH, or NADPH. Phosphate buffer (12.5 mM, pH 7.4) was used to make up the final volume. A parallel incubation without cofactors served as control. A hypoxia condition was induced by gently purging nitrogen gas through the S-9 fraction and phosphate buffer mixture for 10 min in vials sealed with rubber septa and fitted with two needles. Drug and cofactors were then added by injection through the septa without breaking the hypoxia. All incubations were carried out for 30 min at 37 °C.

The incubations were terminated with 3 mL of MeOH, and then the precipitate was separated by centrifugation at 3000 rpm for 15 min. Appropriate aliquots of the supernatant were spotted on TLC plates and eluted with EtOAc/EtOH (9:1). A Uniscan densitometer (Analtech, Newark, DE) was used to quantify the metabolite on TLC plates.

In Vivo Antitumor Assay. The in vivo testing was performed by Medicinal Research Center, CKD Corp., Seoul, Korea. Briefly, 10⁶ P388 leukemia cells were intraperitoneally implanted into male BFD1 mice on day 1; the drug treatment schedule was five daily treatments (day 1 through day 5). The drug, compound 2a, was dissolved in 10% DMSO in distilled water with a total dose of 1000 mg/kg. Groups of 6 animals were used; and there were control groups which consisted of 8 animals.

Results

Chemistry. The monohydroxyethylated 2-{(4-[4-nitrophenoxy]thiophenyl)amino}ethanol (17) and dihydroxethylated 2-{(2-hydroxyethyl)4-[4-nitrophenoxy]phenyl]amino}ethan-1-ol (10a) were prepared by hydroxylation of 4-amino-4′-nitrodiphenyl sulfide with ethylene oxide (Scheme 1). 8,9 The morpholine-containing compound 13a was synthesized by the cyclization of 10a through Mitsunobu reaction (Scheme 1). 10 The N-methylpiperazine-containing compound 15a was prepared through a ring closure method by reacting 4-amino-4′-nitrodiphenyl sulfide with ethylene oxide (Scheme 1). 11 The sulfoxides (10b, 13b, 15b) were synthesized by the alkylation of 4-amino-4′-nitrodiphenyl sulfide with 3-iodopropanol (Scheme 1). 12

Sulfur-Containing 9-Anilinoacridines

Scheme 2

\[
\begin{align*}
\text{NO}_2 & \quad \text{S} & \quad \text{Z} \\
\text{NO}_2 & \quad \text{X} & \quad \text{Y} & \quad \text{Z} \\
10b: X = \text{SO}_2 & & \quad \text{Z} = \text{N(CH}_2\text{CH}_2\text{OH})_3 & \\
10c: X = \text{SO}_2 & & \quad \text{Z} = \text{N(CH}_2\text{CH}_2\text{OH})_2 & \\
10a: X = \text{SO}_2 & & \quad \text{Z} = \text{N(CH}_2\text{CH}_2\text{OH})_4 & \\
10d: X = \text{SO}_2 & & \quad \text{Z} = \text{N(CH}_2\text{CH}_2\text{OH})_5 & \\
13b: X = \text{SO}_2 & & \quad \text{Z} = \text{morpholine}, & \\
13c: X = \text{SO}_2 & & \quad \text{Z} = \text{morpholine}, & \\
13a: X = \text{SO}_2 & & \quad \text{Z} = \text{morpholine}, & \\
15b: X = \text{SO}_2 & & \quad \text{Z} = \text{N-methylpipеразине}, & \\
\end{align*}
\]

*Reagents: (a) H\text{2}O\text{2}, TFA; (b) H\text{2}O\text{2}, (NH\text{4})\text{2}MoO\text{4}.

Scheme 3

\[
\begin{align*}
\text{NO}_2 & \quad \text{S} & \quad \text{O} & \quad \text{Cl} & & \quad \text{a} \\
\text{NO}_2 & \quad \text{S} & \quad \text{O} & \quad \text{N} & \quad \text{N} & \quad \text{CH}_3 & & \quad \text{15c} \\
\end{align*}
\]

*Reagent: (a) N-methylpipеразине.

and 15b) and sulfone 10c were prepared by oxidizing the corresponding sulfides with hydrogen peroxide in trifluoroacetic acid (TFA) (Scheme 2).\(^{8,17}\) The sulfone compound 13c was prepared by oxidizing its sulfide 13a with hydrogen peroxide using ammonium molybdate as catalyst (Scheme 2).\(^{8,18}\) Compound 15c was prepared by reacting 4-chloro-4'-nitrodiphenyl sulfone with N-methylpipеразине (Scheme 3).\(^{12}\)

The amino compounds (7, 11a-c, 14a-c, 16a-c, 18, 20, and 22) were synthesized from the corresponding nitro compounds by reduction with Fe/HCl (Scheme 4).\(^{8}\) The acridine-containing compounds (2a-c, 3, 4a-c, 5a-c, 6, 8, and 9) were synthesized by condensation of their precursors (11a-c, 22, 14a-c, 16a-c, 18, and 20) with 9-chloroacridine, respectively (Scheme 4).\(^{8,19}\)

Cytotoxicity of Target Compounds. The comparative cytotoxicities of compounds 1a and 2a and amsacrine were determined by clonogenic assay with V-79 cells (Table 1). Compound 2a was considerably more cytotoxic (LC\text{90} = 2.1 \mu M) than 1a as well as amsacrine. The unexpected potent cytotoxicity of 2a warranted further studies. Therefore, compounds 3–9 were synthesized for conducting the limited SAR study of compound 2a regarding its cytotoxicity.

It is known that aldehyde oxidase could reduce diaryl sulfoxides to their corresponding sulfides under anaerobic conditions; the sulfoxide and sulfone derivatives (2b, 4b, 5b, 2c, 4c, and 5c) of compounds 2a, 4a, and 5a were therefore synthesized and their cytotoxicities were evaluated, as shown in Table 1, with the expectation of finding potential sulfoxide-containing bioreductive anticancer agents.

Inhibition of Topoisomerase II by 2a. The mechanism by which amsacrine and other DNA-intercalating agents stimulate the production of DNA breaks by topoisomerase II appears to be the primary mechanism of cytotoxicity of this class of drugs.\(^{20}\) On the basis of the structural similarity between 2a and amsacrine, 2a was also evaluated for its topoisomerase II inhibitory activity. The relaxation ability of topoisomerase II was inhibited by 2a to different degrees at concentrations of 10, 100, and 500 \mu M. As in lane 4 of Figure 1, the relaxation activity of topoisomerase II was almost completely inhibited by 500 \mu M of compound 2a.

In Vivo Antitumor Activity of 2a. A preliminary in vivo anticancer screening test showed that 2a was highly effective with ILS of 175 and 2/6 40-day long-term survival against P388 leukemia bearing BFD1 mice as shown in Table 2.

In Vitro Bioreduction of 2b. As stated earlier, compound 2a was highly cytotoxic in vitro against the V-79 cell line and active in vivo against P388 bearing mice. Its metabolic precursor, 2b (6–7-fold less cytotoxic than 2a), was then considered as a candidate bioreductively activated anticancer prodrg. The metabolism profile of compound 2b was studied and is summarized in Table 3.

Discussion

In an attempt to answer whether the acridine moiety contributed to the overall cytotoxicity profile of 1a through a possible intercalating/topoisomerase inhibitory capability, compound 2a, in which both chloroethyl moieties were replaced by a diol functionality, was synthesized. Since the substitution of mustard with bis(2-hydroxyethyl)amino moiety is the only structural difference between 1a and 2a, the hydroxyl groups in the bis(2-hydroxyethyl)amino moiety were suspected to be important for the cytotoxicity of 2a. To test the importance of the bis(2-hydroxyethyl)amino moiety, 4a and 5a were prepared, in which the bis(2-hydroxyethyl)amino moiety was replaced with morpholine and methylpipеразине, respectively. The monohydroxyl group containing compound 6 was prepared to test if both the hydroxyl groups are required. The diol-containing analogue, compound 3, was prepared to test the influences of the distance between the hydroxyl group and the anilino nitrogen as well. On the basis of the structural similarity between compound 2a and SN 12489, compounds 7–9 were designed as the sulfide analogues of SN 12489 instead of sulfonamide.


In this study, V-79 Chinese hamster lung fibroblasts were chosen to evaluate the cytotoxicity of all the synthesized compounds. V-79 cells formed into tightly packed spheroids have been widely used in the evaluation of drug penetration in solid tumors, and radiosensitizing agents and cytotoxic drugs specifically on hypoxia cells.\textsuperscript{1,21} Among compounds 7–9, the electron-donating substituted 7 and 9 were more cytotoxic than the electron-withdrawing nitro-substituted 8. This possibly suggested the involvement of hydrogen bonding, a dipole–dipole electronic effect in drug–receptor interaction, or electronic effects transmitted to the acridine ring, varying its $pK_a$ and DNA binding ability.\textsuperscript{22}

All of the N-alkyl-substituted aniline analogues (2\textsubscript{a}, 3, 4\textsubscript{a}, 5\textsubscript{a}, and 6) were more cytotoxic than the unsubstituted aniline compound 7. The higher homologue of 2\textsubscript{a}, 3, was as potent as 2\textsubscript{a}. Both 2\textsubscript{a} and 3 were more cytotoxic than the

\begin{table}[h]
\centering
\begin{tabular}{llll}
\hline
compd & X & Z & cytotoxicity \(\text{LC}_{90}\) (V-79), \(\mu\text{M}\) \\
\hline
amsacrine & & & 47.5 ± 14.5 \\
1\textsubscript{a} & S & \(\text{N(CH}_2\text{CH}_2\text{OH)}_2\) & >3000 \\
2\textsubscript{a} & S & \(\text{N(CH}_2\text{CH}_2\text{OH)}_2\) & 2.1 ± 0.7 \\
2\textsubscript{b} & SO & \(\text{N(CH}_2\text{CH}_2\text{OH)}_2\) & 15.4 ± 2.5 \\
2\textsubscript{c} & SO\textsubscript{2} & \(\text{N(CH}_2\text{CH}_2\text{OH)}_2\) & 4.8 ± 0.3 \\
3 & S & \(\text{N(CH}_2\text{CH}_2\text{CH}_2\text{OH)}_2\) & 1.9 ± 0.4 \\
4\textsubscript{a} & S & morpholine & 24.9 ± 6.3 \\
4\textsubscript{b} & SO & morpholine & 8.4 ± 2.4 \\
4\textsubscript{c} & SO\textsubscript{2} & morpholine & 7.0 ± 1.9 \\
5\textsubscript{a} & S & \(\text{N-methylpiprazine}\) & 9.4 ± 1.5 \\
5\textsubscript{b} & SO & \(\text{N-methylpiprazine}\) & 3.9 ± 0.4 \\
5\textsubscript{c} & SO\textsubscript{2} & \(\text{N-methylpiprazine}\) & 3.5 ± 0.7 \\
6 & S & \(\text{NH}_2\text{CH}_2\text{CH}_2\text{OH}\) & 10.4 ± 1.5 \\
7 & S & \(\text{NH}_2\) & 46.4 ± 21.7 \\
8 & SO\textsubscript{2} & 588 ± 247 \\
9 & S & OH & 118 ± 38 \\
\hline
\end{tabular}
\caption{In Vitro Cytotoxicity against V-79 Cells by Synthesized Compounds and Amsacrine.}
\end{table}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Topoisomerase II inhibitory assay of compound 2\textsubscript{a}. Reactions indicated above lanes 2–7 were carried out using 6 units of enzyme and 0.25 \(\mu\text{g}\) of supercoiled pRYG DNA each. The reactions were incubated for 30 min at 37 °C. Lane 1 is the standard supercoiled DNA. Lanes 2 and 3 were incubated with or without 10% DMSO. Lanes 4–6 contained 2\textsubscript{a} at concentrations of 500, 100, and 10 \(\mu\text{M}\), respectively. Lane 7 contained amsacrine, 100 \(\mu\text{M}\).}
\end{figure}

acetaldehyde, and 2-hydroxypyrimidine.8 As one of the presence of suitable electron donors such as benzaldehyde, for aldehyde oxidase compared to alkylaryl sulfoxides in the distance between the hydroxyl group and the phenyl ring suggest the importance of the hydroxyl group as well as the.

Table 3. Bioreduction of Compound 2b with Rat S-9 Fractions

<table>
<thead>
<tr>
<th>incubation conditions</th>
<th>bioreductive activitya (μM 2a formation/g of protein per h)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>aerobic</td>
</tr>
<tr>
<td>drug + boiled S-9</td>
<td>nd</td>
</tr>
<tr>
<td>drug + S-9</td>
<td>nd</td>
</tr>
<tr>
<td>drug + 2-hydroxypyrimidine + S-9</td>
<td>nd</td>
</tr>
<tr>
<td>drug + benzaldehyde + S-9</td>
<td>38.14 ± 11.95</td>
</tr>
<tr>
<td>drug + benzaldehyde + menadione + S-9</td>
<td>nd</td>
</tr>
<tr>
<td>drug + NADH + S-9</td>
<td>nd</td>
</tr>
<tr>
<td>drug + NADPH + S-9</td>
<td>nd</td>
</tr>
</tbody>
</table>

a Compound 2a was incubated with boiled rat S-9 fraction, and a standard curve was constructed and was used to estimate the formation of 2a. b Nondetectable.

morpholine-containing 4a and N-methylpiperazine-containing 5a, and 5a was more cytotoxic than 4a. Compound 6, containing a monohydroxyl group, was less cytotoxic than compounds 2a and 3. It is interesting to note that 6 is still considerably more cytotoxic than 9. The above results may suggest the importance of the hydroxyl group as well as the distance between the hydroxyl group and the phenyl ring for the cytotoxicity of the series.

The diaryl sulfoxides were found to be better substrates for aldehyde oxidase compared to alkylaryl sulfoxides in the presence of suitable electron donors such as benzaldehyde, acetaldehyde, and 2-hydroxypyrimidine.9 As one of the requirements for bioreductive activity, potential sulfoxide-containing bioreductive agents should be less cytotoxic than the corresponding metabolites, the sulfides. Of all the diaryl sulfoxide-containing compounds in this study, compound 2b was the only compound which is less cytotoxic than the corresponding sulfide; 2b was 6–7-fold less cytotoxic than 2a. All of the sulfone-containing compounds (2c, 4c, and 5c) were quite potent, and their cytotoxicities were similar. This might indicate that the sulfonyl groups may also contribute to their cytotoxicities. For sulfide-containing as well as sulfoxide-containing compounds (2a, 2b, 4a, 4b, 5a, and 5b), the Z substituent appears to play an important role in providing cytotoxicity. However, the sulfone-containing compounds (2c, 4c, and 5c) may have a possibly different drug–receptor interaction through the influences of the sulfonyl group. The push–pull mechanism for the 1’ sulfonamide group of amsacrine has been proposed to explain the action of amsacrine to topoisomerase II. The sulfonamide oxygen of amsacrine may act as a Lewis base binding to a Lewis acid binding site on topoisomerase II.23 The oxygens of the sulfonyl group might also serve a role similar to that of the sulfonamide oxygens.

Amsacrine was considered to bind to DNA by intercalation of the acridine (the DNA-binding domain) between the base pairs, with the aniline ring (the protein-binding domain) protruding into the minor groove, where it is capable of making contacts with topoisomerase II.1 The topoisomerase II used in the assay is the human 170 kDa isoform. It has been known that the levels of the 170 kDa enzyme are higher in actively growing cells than in stationary-phase cells, and highest during the S phase.24 Our results indicated that compound 2a is a topoisomerase II inhibitor. Although compound 2a appears to be a less potent inhibitor than amsacrine, its cytotoxic potency suggests that low levels of cleavable complexes induced by 2a may be unusually toxic like the triazoloacridone C-1325.25 The inhibition preference among topoisomerase II isoforms and stability of the induced cleavable complexes by drugs could also be important factors contributing to their anticancer activity.26

Benzaldehyde and 2-hydroxypyrimidine are known electron donors for the aldehyde oxidase, and menadione is a known inhibitor for aldehyde oxidase. Our results showed that compound 2b was converted into 2a only in the presence of benzaldehyde and 2-hydroxypyrimidine, and this reduction was inhibited in the presence of menadione. There was no reduction observed when the NADH or NADPH was coincubated with compound 2b and S-9 fraction. These results suggested that compound 2b is a good substrate for aldehyde oxidase, and NADH- or NADPH-dependent enzymes are not involved in the bioreduction of compound 2b.

One of the advantages of the sulfoxide-containing amsacrine


(26) Errington, F.; Willmore, E.; Leontiou, C.; Tilby, M. J.; Austin, C. A. Differences in the longevity of topo IIalpha and topo IIbeta.

VOL. 2, NO. 2 MOLECULAR PHARMACEUTICS 127
analogs is that they are not likely to be metabolized into quinone derivatives as is observed for amsacrine. Quinone- 
eminine derivatives of amsacrine were reported to be respon- 
sible for the side effects of amsacrine through free-radical-
mediated genotoxicity.\textsuperscript{27–29}

In conclusion, the above results suggested the importance 
of hydroxyl functionality along with its location for the 
cytotoxicity of the series. Both diol-containing compounds, 
\( \text{2a} \) and \( \text{3} \), were the most cytotoxic of the sulfide series against 
V-79 cells in vitro (IC\(_{90}\) = 2.1 \( \mu \)M, 1.9 \( \mu \)M, respectively). Among the non-alkyl-substituted compounds (7–9), com-
pounds with electron-donating substitution para to the sulfide 
(7 and 9) were more cytotoxic than the electron-withdrawing 
nitro-substituted compound 8. A preliminary anticancer 
screening against P388 leukemia showed that \( \text{2a} \) is highly 
active in vivo as well. Topoisomerase II inhibitory activity 
appeared to be involved in the cytotoxicity of compound \( \text{2a} \). Sulfoxide compound \( \text{2b} \), which is 6–7-fold less cytotoxic 
than its sulfide \( \text{2a} \), appears to be a potential bioreductive 
anticancer prodrug on the basis of its bioreductive metabo-

Acknowledgment. This was in part supported by 2000 
ITG (Innovative Technology Grant) by the New York State 
Center for Biotechnology. We are grateful to D. J.-K. Kim 
of Medicinal Research Center, CKD Corp., Korea for the in 
vivo testing of \( \text{2a} \).

Supporting Information Available: Table of elemen-
tal analytical data. This material is available free of charge 
via the Internet at http://pubs.acs.org.

\textsuperscript{27} Blasiak, J.; Gloc, E.; Drzewoski, J.; Wozniak, K.; Zadrozny, M.; 
et al. Free radical scavengers can differentially modulate the 
genotoxicity of amsacrine in normal and cancer cells. \textit{Mutat. Res.} 

\textsuperscript{28} Wong, A.; Huang, C.-H.; Crooke, S. T. Deoxyribonucleic acid 
breaks produced by 4′-(9-acridinylamino)methanesulfon-\( m \)-ani-

\textsuperscript{29} Baguley, B. C.; Wakelin, L. P.; Jacintho, J. D.; Kovacic, P. 
Mechanisms of action of DNA intercalating acridine-based 
drugs: how important are contributions from electron transfer and 